Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure

First Affiliated Hospital of Harbin Medical University1 site in 1 country100 target enrollmentJune 2014

ConditionsHeart Failure

InterventionsLidocaine

DrugsLidocaine

Overview

Phase: N/A
Intervention: Lidocaine
Conditions: Heart Failure
Sponsor: First Affiliated Hospital of Harbin Medical University
Enrollment: 100
Locations: 1
Primary Endpoint: All cause mortality
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to evaluate the effect of Cardiac Sympathetic Blockade on Mortality, re-hospitalization rate, symptoms, quality of life, exercise tolerance, cardiac structure, systolic function, electrical activities and concentration of B - type natriuretic peptide precursor in patients with Chronic Heart Failure.

Registry

clinicaltrials.gov

Start Date

June 2014

End Date

January 2019

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

First Affiliated Hospital of Harbin Medical University

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•20-70 years old
•more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
•NYHA functional class III-IV, ejection fraction ≤45%
•NT-proBNP\>400ng/L

Exclusion Criteria

•first episode of acute heart failure
•unrepaired valvular heart disease accompanied with Hemodynamic changes
•hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension
•Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy
•right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease
•overt renal decompensation: serum creatinine\>2.1mg/dl(186umol/L)
•severe hepatic dysfunction, transaminase or alkaline phosphatase \> 3 times the upper limit of normal
•Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc)
•life expectancy shorter than 6 months
•patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination